GlycoMimetics stockholders approve proposed Crescent Biopharma merger

GlycoMimetics (GLYC) announced that its stockholders have approved the proposed merger with Crescent Biopharma, along with all proposals related to the Merger. The proposals were voted upon at GlycoMimetics’ special meeting in lieu of the annual meeting of stockholders held on June 5, 2025, including a reverse stock split of GlycoMimetics’ common stock to be effected at the discretion of the board of directors of GlycoMimetics within the parameters approved by GlycoMimetics’ stockholders. On June 5, 2025, following the Special Meeting, the Board approved a reverse stock split of GlycoMimetics’ common stock at a ratio of 1-for-100. Following the anticipated closing of the Merger, the combined company’s common stock is expected to begin trading on a post-reverse stock split basis on The Nasdaq Capital Market on June 16, 2025, under the new name “Crescent Biopharma, Inc.”, ticker symbol “CBIO”, CUSIP number 38000Q201 and ISIN number US38000Q2012.